Advertisement

P

Chapter
  • 1.2k Downloads

Literatur

  1. 1.
    Pötzl O (1954) Über Palinopsie. Wien Z Nervenh 8:161–186.Google Scholar
  2. 2.
    Pomeranz HD et al. (2000) Palinopsia and polyopia in the absence of drugs or cerebral disease. Neurology 54:855–9.PubMedGoogle Scholar
  3. 3.
    Ogunyemi A, Adams D (1998). Migraine-like symptoms triggered by occipital lobe seizures: response to sumatriptan. Can J Neurol Sci 25:151–3.PubMedGoogle Scholar
  4. 4.
    Silva JA et al. (1997) Resolution of palinopsia with carbamazepine. J Clin Psychiatry; 58:30.PubMedGoogle Scholar
  5. 5.
    Purvin VA Visual disturbance secondary to clomiphene citrate (1995) Arch Ophthalmol 113:482–4.PubMedGoogle Scholar

Literatur

  1. 1.
    Neundörfer B (1987) Polyneuritiden und Polyneuropathien. VCH Verlagsgesellschaft, Weinheim.Google Scholar

Literatur

  1. 1.
    Ceballos-Baumann AO, Obeso JA, Vitek JL, Delong MR, Bakay R, Linazasoro G, Brooks DJ (1994). Restoration of thalamocortical activity following posteroventral pallidotomy in Parkinson’s disease. Lancet 344: 814–14.PubMedGoogle Scholar

Literatur

  1. 1.
    Schlegel U (1998). Paragangliome der Cauda equina. In: Schlegel U, Westphal M (Hrsg.). Neuroonkologie. Thieme, Stuttgart New York 313.Google Scholar
  2. 2.
    Sonneland PR, Scheithauer BW, LeChago J et al. (1986) Paraganglioma of the cauda equina region. Clinicopathologic study of 31 cases with special reference to immunocytology and ultrastructure. Cancer 58:1720–1735.PubMedGoogle Scholar

Literatur

  1. 1.
    Mumenthaler M, Schliack H (1987) Läsionen peripherer Nerven. Thieme, Stuttgart New York.Google Scholar

Literatur

  1. 1.
    Blaes F, Klotz M, Funke D et al. (2002) Disturbance in the serum IgG subclass distribution in patients with anti-Hu positive paraneoplastic neurological syndromes. Eur J Neurol 9:369–372.PubMedCrossRefGoogle Scholar
  2. 2.
    Graus F, Vega F, Delattre JY (1992). Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology 42:536–540.PubMedGoogle Scholar
  3. 3.
    Rauer S, Czygan M, Kaiser R (2002). Quantification of circulating anti-Hu antibody in serial samples from patients with paraneoplastic syndromes: possible correlation of antibody concentration and course of neurological symptoms. J Neurol 249: 285–289.PubMedCrossRefGoogle Scholar
  4. 4.
    Stark E, Wurster U, Patzold U et al (1995). Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol 52:814–818.PubMedGoogle Scholar
  5. 5.
    Sutton I, Winer JB (2002). The immunpathogenesis of paraneoplastic neurological syndromes. Clin Sci 102:475–486.PubMedCrossRefGoogle Scholar
  6. 6.
    Uchuy M, Graus F, Vega F et al. (1996) Intravenous immunglobulin therapy in paraneoplastic neurologic syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry 60:388–392.Google Scholar
  7. 7.
    Verschuuren J, Dalmau J. (1998). Paraneoplastic neurological disorders. In: Antel J, Birnbaum G, Hartung HP. Clininical Neuroimmunology. Blackwell Science, London pp. 148–171.Google Scholar
  8. 8.
    Voltz R (2002). Paraneoplastic neurological syndromes: An update on diagnosis, pathogenesis and therapy. Lancet Neurology 1:294–305.PubMedGoogle Scholar

Literatur

  1. 1.
    Mumenthaler M, Schliack H (1987) Läsionen peripherer Nerven. Thieme, Stuttgart New York.Google Scholar

Literatur

  1. 1.
    Parkinson Study Group (2000). Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Jama, 284:1931–8.CrossRefGoogle Scholar
  2. 2.
    Parkinson Study Group (2001). Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med, 345:956–63.Google Scholar
  3. 3.
    Ceballos-Baumann AO (1999). Idiopathisches Parkinson-Syndrom. In: Berlit P (editor) Facharztbuch: Klinische Neurologie. Springer-Verlag, Heidelberg 863–86.Google Scholar
  4. 4.
    Gelb DJ, Oliver E, Gilman S (1999). Diagnostic criteria for Parkinson disease. Arch Neurol, 56:33–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Hughes AJ, Lees AJ, Stern GM (1991). Challenge tests to predict the dopaminergic response in untreated Parkinson’s disease. Neurology 41: 1723–1725.PubMedGoogle Scholar
  6. 6.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992). Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184.PubMedGoogle Scholar
  7. 7.
    Mena L, Cotzias GC (1975). Protein intake and treatment of Parkinson’s disease with levodopa. New Engl J Med 292: 181–184.PubMedCrossRefGoogle Scholar
  8. 8.
    Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE (2002). Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 58:11–7.PubMedGoogle Scholar
  9. 9.
    Montastruc JL, Rascol O, Senard JM, Rascol A (1994). A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson’s disease: a five year follow up. J Neurol Neurosurg Psychiatry, 57:1034–8.PubMedGoogle Scholar
  10. 10.
    Nutt JG, Woodward WR, Hammerstad JP et al. (1984). The ‘on-off’ phenomenon in Parkinson’s disease. Relation to levodopa absorption and transport. N Engl J Med 310: 483–488.PubMedCrossRefGoogle Scholar
  11. 11.
    Pincus JH, Barry K (1987). Influence of dietary protein on motor fluctuations in Parkinson’s disease. Arch Neurol 44: 270–272.PubMedGoogle Scholar
  12. 12.
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000). A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med, 342:1484–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Masso J et al. (1997) Cabergoline in the treatment of early parkinsons disease: results of the first year of treatment in a double blind comparison of cabergoline and levodopa. Neurology, 48:363–368.PubMedGoogle Scholar
  14. 14.
    Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998). Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology, 50:1323–6.PubMedGoogle Scholar

Literatur

  1. 1.
    Fitzgerald PM, Jankovic J (1989). Lower body parkinsonism. Evidence for vascular etiology. Mov Disord 4: 249–260.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    DiMascio A, Bernardo DL, Greenblatt D, Marder JE (1976). A controlled trial of amantadine in drug induced extrapyramidal disorders. Arch Gen Psychiatry 33: 599–602.PubMedGoogle Scholar
  2. 2.
    Hardie RJ, Lees AJ (1988). Neuroleptic induced Parkinson’s syndrome: a clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 51: 850–854.PubMedGoogle Scholar
  3. 3.
    Kelly JT, Zimmerman RL, Abuzzahab FS, Schiele BC (1974). A double-blind study of amantadine HCL versus benztropene mesylate in drug-induced parkinsonism. Acta Psychiatr Scand 212: 44–51.Google Scholar
  4. 4.
    Mindham RHS, Gaind R, Anstee BH, Rimmer L (1972). Comparison of amantadine, orphenadrine and placebo in drug induced parkinsonism. Pschol Med 2: 406–443.Google Scholar
  5. 5.
    Villeneuve (1972). The Rabbit syndrome: a peculiar extrapyramidal reaction. Canad Psychiat Assoc J 17(suppl): 69–72.Google Scholar

Literatur

  1. 1.
    Berlit P (1999) Erkrankungen der Hirnnerven und des Hirnstamms. In: Berlit P (Hrsg.) Klinische Neurologie, Springer-Verlag, Berlin, Heidelberg, S 352–407.Google Scholar
  2. 2.
    Portier F, Faulcon P, Lamblin B, Bonfils P (2000) Semiologie, etiologies et evolution des parosmies: a propos de 84 cas. Ann Otolaryngol Chir Cervicofac 117: 12–18.PubMedGoogle Scholar

Literatur

  1. 1.
    Raymond GV. Peroxisomal disorders. Curr Opin Pediatr 1999; 11:572–576PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Mena H, Nakazato Y, Jouvet A et al. (2000) Pineal Parenchymal Tumours. In: Kleihues P, Cavenee WK (Hrsg.) Tumours of the Nervous System. WHO Classification of Tumors. IARC Press, Lyon 115–121.Google Scholar
  2. 2.
    Albuquerque FC, Amar AP, Apuzzo MLJ (2000). Pineal Region Tumors. In: Bernstein M, Berger MS (Hrsg.) Neuro-Oncology. The Essentials. Thieme; New York. 338–351.Google Scholar
  3. 3.
    Winkler D (1998). Tumoren der Pinealis. In: Schlegel U, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart New York 239–249.Google Scholar
  4. 4.
    Bode U, Fleischhack G (1998). Tumoren des Nervensystems im Kindesalter. In: Schlegel U, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart New York. 342–375.Google Scholar

Literatur

  1. 1.
    Sadda SR et al. Clinical spectrum of PION. Am J Ophthalmol 2001; 132:743–750PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Benson ER, Schutzer SF (1999) Posttraumatic piriformis syndrome: diagnosis and results of operative treatment. J Bone Joint Surg Am 81: 941–949.PubMedGoogle Scholar
  2. 2.
    Hanania M, Kitain E (1998) Perisciatic injection of steroid for the treatment of sciatica due to piriformis syndrome. Reg Anesth Pain Med 23: 223–228.PubMedGoogle Scholar
  3. 3.
    Silver JK, Leadbetter WB (1998) Piriformis syndrome: assessment of current practice and literature review. Orthopedics 21: 1133–1135.PubMedGoogle Scholar

Literatur

  1. 1.
    Abel JJ, Rowentree LG, Turner BB (1914). Plasma removal with return or corpuscles (plasmapheresis). J Pharmakol Exp Ther 5:625–641.Google Scholar
  2. 2.
    Gurland H.J.(1983) Report from the commitee on standardization of nomenclature. In: Lysaght MJ, Gurland HJ (eds). Plasma separation and plasma fractionation, Schatthauer Verlag, New York Stuttgart, pp 1–10.Google Scholar
  3. 3.
    Pineda AA (1999). Selective therapeutic extraction of plasma constiuents, revisited. Transfusion 39:671–673.PubMedGoogle Scholar
  4. 4.
    Subcommittee of the American Academy of Neurology. (1996) Assessment of plasmapheresis. Report of the therapeutics and technology. Neurology 47:840–843.Google Scholar
  5. 5.
    Toepfer M, Schiffl H, Sitter T et al. (1999). Extracorporeal antibody elimination in neuroimmunological diseases. Ther Apher 3:268–270.PubMedGoogle Scholar
  6. 6.
    Schneidewind JM, Zettl UK, Winkler RE et al. (1999) Therapeutic apheresis in myasthenia gravis patients: A six years follow up. Therapeutic Apheresis Vol 3(4):298–302.PubMedCrossRefGoogle Scholar
  7. 7.
    Morosetti M, Meloni C, Caramia M et al. (1998) Plasmapheresis in severe forms of myasthenia gravis. Artif Organs 22(2):129–134.PubMedCrossRefGoogle Scholar
  8. 8.
    Hughes RAC, Swan AV, Cornblath DR et al. (1997) Randomised trial of plasma exchange, intravenous immunoglobulins and combined treatments in Guillain-Barre syndrome. Lancet 349: 225–230.Google Scholar
  9. 9.
    Multiple-Sklerose-Therapie-Konsensus-Gruppe (MSTKG) (2002). Immunmodulatorische Stufentherapie der Multiplen Sklerose. Nervenarzt 73:556–563.Google Scholar
  10. 10.
    Weinshenker BG, O’Brien PC, Petterson TM et al. (1999) A randomised trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann.Neurol. 46(6):878–886.PubMedCrossRefGoogle Scholar
  11. 11.
    Keegan, M, Pineda A, McClelland R (2002). Plasma exchange for severe atttacks of CNS demyelination: predictors of response. Neurology 58:143–146.PubMedGoogle Scholar
  12. 12.
    Weilbach FX, Gold R (1999). Pathogenese, Diagnostik und Therapie von Autoimmunneuropathien. In: Zettl U.K, Mix E. (Hrsg.). Klinische Neuroimmunologie. de Gruyter, Berlin New York S. 175–190.Google Scholar
  13. 13.
    Motomura M, Hamasaki S, Nakane S et al (2000) Apheresis treatment in Lambert-Eaton myasthenic syndrome. Ther Apher 4:287–290.PubMedGoogle Scholar
  14. 14.
    Shumak KH, Rock GA (1984). Therapeutic plasma exchange. N Engl J Med 310:762–771.PubMedCrossRefGoogle Scholar
  15. 15.
    Bambauer R (1997). Therapeutischer Plasmaaustausch und verwandte Plasmaseparationsverfahren. Pabst, Lengerich Berlin S. 8–11.Google Scholar
  16. 16.
    Gold R, Toyka KV (2001). Immuntherapie neurologischer Erkrankungen. Uni med Bremen, London.Google Scholar
  17. 17.
    Rizvi MA, Vesely SK, George JN et al. (2000) Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpurahemolyticuremic syndrome. Transfusion 40: 896–901.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Wiestler OD (1998). Pathologische Anatomie und WHO-Klassifikation der Tumoren des Nervensystems. In: Schlegel U, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart New York 4–47.Google Scholar
  2. 2.
    Westphal M (1998). Ventrikeltumoren. In: Schlegel U, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart New York 205–211.Google Scholar
  3. 3.
    Rock J (2000). Pilocytic Astrocytoma and other indolent Tumors. In: Bernstein M, Berger MS (Hrsg.) Neuro-Oncology. The Essentials. Thieme, New York 319–328.Google Scholar

Literatur

  1. 1.
    Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL (1980) Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Medicine 59: 311–322.PubMedGoogle Scholar
  2. 2.
    Enevoldson TP, Harding AE (1992) Improvement in the POEMS syndrome after administration of tamoxifen. J Neurol Neurosurg Psychiatry 55: 71–72.PubMedGoogle Scholar
  3. 3.
    Rotta FT, Bradley WG (1997) Marked improvement of severe polyneuropathy associated with multifocal osteosclerotic myeloma following surgery, radiation, and chemotherapy. Muscle Nerve 20: 1035–1037.PubMedCrossRefGoogle Scholar
  4. 4.
    Simmons Z (1999) Paraproteinemia and neuropathy. Curr Opin.Neurol 12: 589–595.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Zimmerman RK, Spann SJ (1999) Poliovirus vaccine options. Am Fam Physician 59: 113–118, 125–126.PubMedGoogle Scholar

Literatur

  1. 1.
    Lim SS et al. The use of low-dose prednisone in the management of rheumatoid arthritis. Bull Rheum Dis 2001; 50:1–4PubMedGoogle Scholar
  2. 2.
    StClair EW. Infliximab therapy for rheumatic disease: clinical and radiologic efficacy. Ann Rheum Dis 2002; 61Suppl.2:II67–II69Google Scholar

Literatur

  1. 1.
    Evans JM, Hunder GG. Polymyalgia rheumatica and giant cell arteritis. Clin Geriatr Med 1998; 14:455–473.)PubMedGoogle Scholar
  2. 2.
    Gabriel SE et al. Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997; 40:1873–8.PubMedGoogle Scholar
  3. 3.
    Goodwin JS. Progress in gerontology: polymyalgia rheumatica and temporal arteritis. J Am Geriatr Soc 1992; 40:515–525PubMedGoogle Scholar
  4. 4.
    Labbe P. et al. Epidemiology and optimal management of polymyalgia rheumatica. Drugs Aging 1998; 13:109–18PubMedGoogle Scholar

Literatur

  1. 1.
    Adams RD, Victor M, Ropper AH (Hartung H-P, Poewe W, Reichmann H: Deutsche Ausgabe) (1999). Prinzipien der Neurologie. McGraw-Hill, Maidenhead, Frankfurt.Google Scholar
  2. 2.
    Engelhardt A (1999). Polyneuropathien. In: Berlit P. (Hrsg.) Klinische Neurologie. Springer-Verlag, Berlin Heidelberg New York S. 409–433.Google Scholar
  3. 3.
    Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF (eds) (1993). Peripheral neuropathy, 3rd edn. Saunders, Philadelphia London.Google Scholar

Literatur

  1. 1.
    Dyck PJ, Daube J, O’Brien P, et al. (1986) Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314:461–465.PubMedCrossRefGoogle Scholar
  2. 2.
    Dyck PJ, O’Brien PC, Oviatt KF, et al. (1982) Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11:136–141.PubMedCrossRefGoogle Scholar
  3. 3.
    Hadden RD, Sharrack B, Bensa S, et al. (1999) Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 53:57–61.PubMedGoogle Scholar
  4. 4.
    Hartung HP, Reiners K, Toyka KV, Ollard JD (1994). Guillain-Barre syndome and CIDP. In: Hohlfeld R, editor. Immunology of Neuromuscular Disease. Dordrecht: Kluver pp.39–104.Google Scholar
  5. 5.
    Hodgkinson SJ, Pollard JD, McLeod JG (1990). Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 53:327–330.PubMedGoogle Scholar
  6. 6.
    Hughes RA (2002). Systematic reviews of treatment for inflammatory demyelinating neuropathy. J Anat 200(4):331–339.PubMedCrossRefGoogle Scholar
  7. 7.
    Molenaar DSM, van Doorn PA, Vermeulen M (1997). Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: A pilot study. J Neurol Neurosurg Psychiatry 62:388–390.PubMedGoogle Scholar
  8. 8.
    Pollard JD (2002). Chronic inflammatory demyelinating polyradiculoneuropathy. Curr Opin Neurol 15(3):279–283.PubMedCrossRefGoogle Scholar
  9. 9.
    Said G (2002). Chronic inflammatory demyelinative polyneuropathy. J Neurol 249:245–253.PubMedCrossRefGoogle Scholar
  10. 10.
    van Doorn PA, Brand A, Stengers FP, et al. (1990) High-dose intravenous immunoglobulin treatment in chronic demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40:209–212.PubMedGoogle Scholar
  11. 11.
    Van Doorn PA, Garssen MP (2002). Treatment of immune neuropathies. Curr Opin Neurol 15(5):623–631.PubMedGoogle Scholar

Literatur

  1. 1.
    Amato AA, Barohn RJ (2001) Diabetic Lumbosacral Polyradiculoneuropathies. Current Treatment Options Neurology 3: 139–146Google Scholar
  2. 2.
    Zochodne DW (2000) Diabetic Neuropathies. Current Treatment Options Neurology 2: 23–29Google Scholar

Literatur

  1. 1.
    Low PA, McLeod JG (1993) The autonomic neuropathies. In: Low PA (ed.): Clinical Autonomic Disorders. Evaluation and Management. Little, Brown & Comp., Boston, Toronto, London, 395–421.Google Scholar
  2. 2.
    Zochodne DW (2000) Diabetic Neuropathies. Current Treatment Options Neurology 2: 23–29.Google Scholar

Literatur

  1. 1.
    Hartung HP, van der Meché FGA, Pollard JD (1998) Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies. Current Opinion in Neurology 11: 497–513.PubMedGoogle Scholar

Literatur

  1. 1.
    Anders HJ, Goebel FD (1999) Neurological manifestations of cytomegalovirus infection in the acquired immunodeficiency syndrome. Int J STD AIDS 10: 151–159.PubMedGoogle Scholar
  2. 2.
    Wulff EA, Wang AK, Simpson DM (2000) HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs 59: 1251–1260.PubMedGoogle Scholar

Literatur

  1. 1.
    Perkins AT, Morgenlander JC (1997) Endocrinologic causes of peripheral neuropathy. Pins and needles in a stocking-and-glove pattern and other symptoms. Postgrad Med 102: 81–82, 90–92, 102–106.PubMedGoogle Scholar

Literatur

  1. 1.
    Neundörfer B (1987) Polyneuritiden und Polyneuropathien. VCH Verlagsgesellschaft, Weinheim.Google Scholar

Literatur

  1. 1.
    Collins M, Kissel J, Mendell J (1998) Vasculitic neuropathies. In: Clinical neuroimmunology. Antel J, Birnbaum G, Hartung HP (editors), 316–339.Google Scholar

Literatur

  1. 1.
    Donaghy M, Mills KR, Boniface SJ, Simmons J, Wright I, Gregson N, Jacobs J (1994) Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 57: 778–783.PubMedGoogle Scholar
  2. 2.
    Jaspert A, Claus D, Grehl H, Neundörfer B (1996) Multifocal motor neuropathy: clinical and electrophysiological findings. J Neurol 243: 684–692.PubMedCrossRefGoogle Scholar
  3. 3.
    Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E (1997) Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 63: 765–769.PubMedGoogle Scholar
  4. 4.
    Van den Berg LH, Franssen H, Wokke JHJ (1998) The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 121: 421–428.PubMedGoogle Scholar
  5. 5.
    Van den Berg-Vos RM, van den Berg LH, Franssen H, Wokke JHJ, van Doom PA, Martina ISJ (1999) Treatment of multifocal motor neuropathy with interferon β-1A. JPNS 4: 206.Google Scholar

Literatur

  1. 1.
    Comi G, Corbo M (1998) Metabolic neuropathies. Curr Opin Neurol 11: 523–529.PubMedGoogle Scholar
  2. 2.
    Kuwabara S, Nakazawa R, Azuma N, Suzuki M, Miyajima K, Fukutake T, Hattori T (1999) Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients. Intern Med 38: 472–475.PubMedGoogle Scholar
  3. 3.
    Pirzada NA, Morgenlander JC (1997) Peripheral neuropathy in patients with chronic renal failure. A treatable source of discomfort and disability. Postgrad Med 102: 249–261.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Dropcho EJ (1999) Paraneoplastic Diseases of the Nervous System. Curr Treat Options Neurol 1: 417–427.PubMedGoogle Scholar
  2. 2.
    Oh SJ, Dropcho EJ, Claussen GC (1997) Anti-Hu-associated paraneoplastic sensory neuronopathy responding to early aggressive immunotherapy: report of two cases and review of the literature. Muscle Nerve 20: 1576–1582.PubMedGoogle Scholar

Literatur

  1. 1.
    Berlit P (1999) Klinische Neurologie. Springer-Verlag, Berlin Heidelberg.Google Scholar
  2. 2.
    Dyck PJ, Low PA, Windebank AJ et al (1991) Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 325: 1482–1486.PubMedCrossRefGoogle Scholar
  3. 3.
    Latov N (2000) Prognosis of neuropathy with monoclonal gammopathy. Muscle Nerve 23: 150–152.PubMedCrossRefGoogle Scholar
  4. 4.
    Mariette X, Chastang C, Clavelou P, Louboutin JP, Leger JM, Brouet JC (1997) A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 63: 28–34.PubMedCrossRefGoogle Scholar
  5. 5.
    Oksenhendler E, Chevret S, Leger JM, Louboutin LP, Bussel A, Brouet JC, (1995) Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM-gammopathy. J Neurol Neurosurg Psychiatry 59: 243–247.PubMedCrossRefGoogle Scholar
  6. 6.
    Rudnicki SA, Harik SI, Dhodapkar M, Barlogie B, Eidelberg D (1998) Nervous system dysfunction in Waldenström’s macroglobulinemia: response to treatment. Neurology 51: 1210–1213.PubMedGoogle Scholar
  7. 7.
    Simmons Z (1999) Paraproteinemia and neuropathy. Curr Opin.Neurol 12: 589–595.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Walker A, Tyor W (2001) Neurosarcoidosis. Curr Treat Options Neurol 3: 529–535.PubMedGoogle Scholar

Literatur

  1. 1.
    Grehl H, Reinhardt F (2000) Checkliste Neurologie. Thieme, Stuttgart New York.Google Scholar

Literatur

  1. 1.
    Mumenthaler M, Schliack H (1987) Läsionen peripherer Nerven. Thieme, Stuttgart New York.Google Scholar
  2. 2.
    Olehnik WK, Manske PR, Szerzinski J (1994) Median nerve compression in the proximal forearm. J Hand Surg 19: 121–126.Google Scholar

Literatur

  1. 1.
    Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial (2001). Lancet 357(9270):1729–37.Google Scholar
  2. 2.
    Diethrich EB, Ndiaye M, Reid DB (1996). Stenting in the carotid artery: initial experience in 110 patients. J Endovasc Surg 3(1):42–62.PubMedGoogle Scholar
  3. 3.
    Robbin ML, Lockhart ME, Weber TM, Vitek JJ, Smith JK, Yadav J, Mathur A, Iyer SS, Roubin GS (1997). Carotid artery stents: early and intermediate follow-up with Doppler US. Radiology 205(3):749–56.PubMedGoogle Scholar
  4. 4.
    Yadav JS, Roubin GS, Iyer S, Vitek J, King P, Jordan WD, Fisher WS (1997). Elective stenting of the extracranial carotid arteries. Circulation 95(2):376–81.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Personalised recommendations